top of page


Mucommune
Advancing Innovations to Promote Female Reproductive Health
-
First in-class platform for harnessing the synergy between antibodies and mucus to reinforce the mucus barrier for mucosal health
-
Proprietary intravaginal ring technologies for sustained delivery of small molecules to biomacromolecules
-
Unparalleled safety from topical delivery
Latest News
Our lead contraceptive mAb candidate is published in Science Translational Medicine. UNC Chapel Hill Press release. Media coverage:
The Scientist, Wired Magazine, MedScape, WRAL TechWire.
Inhalon, our sister company, announces partnership with Celltrion and initiates Phase 1 and 2 clinical trial.
March 11th, 2021 - Mucommune in consortium that initiates first-ever clinical trial for a contraceptive mAb (ClinicalTrials.gov, NCT04731818).
bottom of page